Christos Sotiriou

Research interests

Publications

• 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00007-3

• The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

  npj Breast Cancer · 2021 · https://doi.org/10.1038/s41523-021-00346-1

• Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

  npj Breast Cancer · 2020 · https://doi.org/10.1038/s41523-020-0156-0

• The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice

  The Journal of Pathology · 2020 · https://doi.org/10.1002/path.5406

• The 2019 World Health Organization classification of tumours of the breast

  Histopathology · 2020 · https://doi.org/10.1111/his.14091

• Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis

  Nature · 2020 · https://doi.org/10.1038/s41586-020-03046-1

• Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.18.01010

• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

  Advances in Anatomic Pathology · 2017 · 10.1097/pap.0000000000000161

• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourina

  Advances in Anatomic Pathology · 2017 · https://doi.org/10.1097/pap.0000000000000161

• HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

  Nature Medicine · 2017 · https://doi.org/10.1038/nm.4292

• Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

  Advances in Anatomic Pathology · 2017 · https://doi.org/10.1097/pap.0000000000000162

• Genomic Characterization of Primary Invasive Lobular Breast Cancer

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.64.0334

• Landscape of somatic mutations in 560 breast cancer whole-genome sequences

  Nature · 2016 · https://doi.org/10.1038/nature17676

• 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1602253

• Subclonal diversification of primary breast cancer revealed by multiregion sequencing

  Nature Medicine · 2015 · 10.1038/nm.3886

• Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity

  Nature · 2015 · https://doi.org/10.1038/nature14665

• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu450

• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

  Annals of Oncology · 2014 · 10.1093/annonc/mdu112

• Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

  Journal of Clinical Oncology · 2014 · 10.1200/jco.2014.58.1967

• PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2014.55.7876

• Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2013.54.1870

• CD4+ follicular helper T cell infiltration predicts breast cancer survival

  Journal of Clinical Investigation · 2013 · 10.1172/jci67428

• Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2011.41.0902

• Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds586

• Dissecting the Heterogeneity of Triple-Negative Breast Cancer

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.38.2010

• The landscape of cancer genes and mutational processes in breast cancer

  Nature · 2012 · 10.1038/nature11017

• Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

  JNCI Journal of the National Cancer Institute · 2011 · https://doi.org/10.1093/jnci/djr393

• Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

  Clinical Cancer Research · 2007 · 10.1158/1078-0432.ccr-06-2765

• Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

  JNCI Journal of the National Cancer Institute · 2006 · https://doi.org/10.1093/jnci/djj052

• Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

  JNCI Journal of the National Cancer Institute · 2006 · 10.1093/jnci/djj329

• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  Proceedings of the National Academy of Sciences · 2003 · 10.1073/pnas.1732912100

Current projects

No projects listed.